Bryan Johnson's Blueprint Supplements: What the Science Actually Says

Bryan Johnson is the most documented human longevity experiment in history. The founder of Kernel and OS Fund, Johnson has spent millions of dollars building a 24-person medical team that monitors virtually every measurable biomarker, tests over 100 supplements and pharmaceuticals, and publishes detailed monthly reports on his results. His stated goal: to have the organs of an 18-year-old at age 45.

Whether or not you find the project credible, Johnson's Blueprint protocol has forced the longevity community to engage with questions it would rather avoid: Which interventions have evidence? Which are purely experimental? And what is the honest risk-benefit trade-off of aggressive supplementation?

**The Blueprint Supplement Stack — Tiered by Evidence**

Johnson's reported daily stack includes 100+ compounds. The following tiers reflect Everspan's evidence-grading methodology applied to the most prominent Blueprint supplements:

**Tier 1 — Strong Human Evidence (Grade A/B+):** - *Creatine monohydrate (5g/day)* — Grade A. Johnson includes creatine for cognitive and muscular benefits. Perhaps the most validated supplement in existence, with consistent human trial data on muscle mass, strength, recovery, and emerging data on brain creatine stores and cognitive function. - *Omega-3 fatty acids (4.51g EPA + 2.83g DHA)* — Grade A. Johnson takes unusually high doses of omega-3. Meta-analyses consistently show triglyceride reduction, cardiovascular risk reduction, and anti-inflammatory effects at doses 1–4g/day EPA+DHA. - *Vitamin D3 + K2* — Grade B+. Johnson maintains 25-OH-D above 60 ng/mL. Vitamin D deficiency is near-universal in adults over 40; correcting it has downstream effects on testosterone, immune function, and bone density. - *Magnesium (3 forms)* — Grade B+. Johnson uses glycinate, malate, and threonate. Magnesium is a cofactor for over 300 enzymatic reactions; deficiency impairs sleep, blood pressure regulation, and insulin sensitivity.

**Tier 2 — Moderate Evidence (Grade B/B-):** - *NMN/NR (900mg/day NMN)* — Grade B-. Johnson takes high-dose NMN. Human trials confirm blood and tissue NAD+ elevation, with meaningful but modest effect sizes on insulin sensitivity and metabolic markers. The translation to longevity outcomes in humans is not yet established. - *Lycopene (45mg/day)* — Grade B. High-dose lycopene has been associated with reduced prostate cancer risk and cardiovascular benefit in observational studies, with modest randomized trial support. - *Ashwagandha (600mg/day)* — Grade B. Johnson includes ashwagandha for stress hormones and testosterone support. RCT data shows meaningful cortisol and testosterone effects; longer-term safety data is less characterized. - *CoQ10 (100mg ubiquinol)* — Grade B. Mitochondrial ATP production support; particularly relevant for anyone on statins, which deplete CoQ10.

**Tier 3 — Experimental / Limited Human Data (Grade C or below):** - *Rapamycin (13mg weekly)* — Grade C. The most controversial element of Johnson's protocol. mTOR inhibition is one of the most reproducible longevity interventions in animal models; the human trial data is sparse, and the immunosuppressive risks at weekly dosing are real. Johnson monitors immune markers intensively. - *Metformin (1,500mg/day)* — Grade C for longevity in non-diabetics. Robust data in type 2 diabetes; the TAME trial is testing metformin in healthy aging. Johnson has cycled on and off based on exercise performance data (metformin may blunt training adaptations). - *Testosterone therapy* — Grade B for symptomatic hypogonadism. Johnson uses testosterone with careful monitoring. Age-matched reference ranges likely underdiagnose functional hypogonadism in men over 40. - *Lithium orotate (1mg/day)* — Grade C. Micro-dose lithium has been associated with longevity in epidemiological studies; no RCT data for healthy adults.

**What's Missing From the Evidence Picture**

Several Blueprint compounds have almost no human longevity data: Plasmalogens, Ca-AKG, and various peptides like BPC-157 and Epithalon. Johnson is arguably self-experimenting with these. The fact that he is rigorously measuring doesn't mean effects translate — his n=1 design cannot establish causation.

**What You Can Realistically Adopt**

The highest-signal interventions from Blueprint that are accessible, safe, and have meaningful human evidence:

1. *Creatine monohydrate* — 5g/day, cheapest per-effect supplement available 2. *Omega-3 (EPA+DHA)* — 2–4g/day from high-quality fish oil 3. *Vitamin D3* — 2,000–5,000 IU/day with K2 (100mcg MK-7) 4. *Magnesium glycinate* — 200–400mg before bed 5. *CoQ10 ubiquinol* — 100–200mg (essential if on statins) 6. *NMN or NR* — 250–500mg/day if NAD+ decline is a concern (see our NMN vs NR guide)

The aspirational items — rapamycin, metformin for non-diabetics, growth hormone peptides — require physician involvement, careful monitoring, and risk tolerance that most people cannot replicate outside a clinical context.

**The Bottom Line**

Bryan Johnson's Blueprint is part inspiration, part marketing, and part genuine scientific contribution. His commitment to measurement is admirable; his transparency about failures (he publicly reports when biomarkers worsen) is unusual. The core lesson is not to replicate his exact stack — it is to take longevity seriously enough to measure your own biomarkers, optimize the high-evidence fundamentals, and approach experimental compounds with appropriate humility.